新型玻璃体内双转基因遗传药物治疗新生血管性视网膜病变的设计与表征
研究在非人灵长类中进行定向进化,获得可穿越玻璃体视网膜屏障的AAV变体R100,并构建携带编码阿柏西普序列与抑制VEGF-C的microRNA的双转基因药物4D-150。体外及非人灵长类中4D-150转导良好、双转基因表达稳健;激光诱导脉络膜新生血管模型中各测试剂量均完全预防临床相关血管生成病变。
要点
- R100在体外和体内视网膜细胞转导方面优于AAV2。
- 4D-150在人视网膜色素上皮细胞中呈剂量依赖性转基因表达,并相应降低VEGF-A和VEGF-C。
- 非人灵长类玻璃体内给予4D-150耐受良好,激光诱导脉络膜新生血管模型中各测试剂量均完全预防临床相关血管生成病变。
核心结论
- 4D-150在体外和nonhuman primates(NHP)中实现视网膜双转基因稳健表达,在激光诱导脉络膜新生血管模型中各测试剂量均完全预防临床相关血管生成病变,这些发现支持进一步开发4D-150。
研究设计与样本
- 在nonhuman primates(NHP)中进行定向进化,获得可穿越玻璃体视网膜屏障并转导视网膜各区域与各层的腺相关病毒(AAV)变体R100。
- 构建基于R100的遗传药物4D-150,携带编码阿柏西普的密码子优化序列(抑制VEGF-A、VEGF-B和PlGF)及抑制VEGF-C表达的microRNA序列。
- 在人视网膜细胞体外及NHP体内表征转导、转基因表达与生物学活性。
主要发现
- R100在体外和体内视网膜细胞转导方面优于AAV2。
- 4D-150转导人视网膜色素上皮细胞后呈剂量依赖性转基因表达,并相应降低VEGF-A和VEGF-C。
- NHP玻璃体内给予4D-150耐受良好,视网膜中双转基因表达稳健。
- 激光诱导脉络膜新生血管灵长类模型中,4D-150在各测试剂量均完全预防临床相关血管生成病变。
临床怎么用
- 作者结论为这些发现支持进一步开发4D-150;临床试验正在进行,以确定4D-150在湿性AMD和DME患者中的安全性和有效性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intravitreal delivery of therapeutic transgenes to the retina via engineered viral vectors can provide sustained local concentrations of therapeutic proteins and thus potentially reduce the treatment burden and improve long-term vision outcomes for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy. METHODS: We performed directed evolution in nonhuman primates (NHP) to invent an adeno-associated viral (AAV) variant (R100) with the capacity to cross vitreoretinal barriers and transduce all regions and layers of the retina following intravitreal injection. We then engineered 4D-150, an R100-based genetic medicine carrying 2 therapeutic transgenes: a codon-optimized sequence encoding aflibercept, a recombinant protein that inhibits VEGF-A, VEGF-B, and PlGF, and a microRNA sequence that inhibits expression of VEGF-C. Transduction, transgene expression, and biological activity were characterized in human retinal cells in vitro and in NHPs. RESULTS: R100 demonstrated superior retinal cell transduction in vitro and in vivo compared to AAV2, a commonly used wild-type AAV serotype in retinal gene therapies. Transduction of human retinal pigment epithelial cells in vitro by 4D-150 resulted in dose-dependent transgene expression and corresponding reductions in VEGF-A and VEGF-C. Intravitreal administration of 4D-150 to NHPs was well tolerated and led to robust retinal expression of both transgenes. In a primate model of laser-induced choroidal neovascularization, 4D-150 completely prevented clinically relevant angiogenic lesions at all tested doses. CONCLUSIONS: These findings support further development of 4D-150. Clinical trials are underway to establish the safety and efficacy of 4D-150 in individuals with wet AMD and DME.
引用
- Calton MA, Croze RH, Burns C, et al. Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies. Invest Ophthalmol Vis Sci. 2024. PMID: 39620832. doi:10.1167/iovs.65.14.1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。